NCT05338931View on ClinicalTrials.gov

Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

March 15, 2022

Primary Completion Date

March 15, 2030

Study Completion Date

September 15, 2030

Conditions
B-cell Non Hodgkin Lymphoma
Interventions
DRUG

AT101(Anti-CD19 Chimeric Antigen Receptor T cell)

Anti-CD19 Chimeric Antigen Receptor T cell

Trial Locations (1)

Unknown

RECRUITING

Asan Medical Center, Seoul

Sponsors

Lead Sponsor

AbClon
All Listed Sponsors
lead

AbClon

INDUSTRY

NCT05338931 - Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter